Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Epirubicin and paclitaxel were administered either in combination or sequentially to 202 patients with metastatic breast cancer to demonstrate noninferiority of the sequential approach. Response rates and survival were comparable in the 2 groups, but toxicity was greater (neutropenia and neuropathy) in those that received the drugs sequentially rather than in combination.

Rethinking Combination Chemotherapy: Concomitant vs Sequential Drug Treatment for Breast Cancer